SEC Form 4 · accession 0001179110-18-001967

Traws Pharma, Inc. · TRAW

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 8, 2018

Accepted (ET)

Feb 12, 2018 · 5:20 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001130598

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 8, 2018	P$0	50,000	—	A	86,321	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (right to purchase)^F1,F2	$1.01	Feb 8, 2018	P	50,000	A	Feb 8, 2018	—	Series A Convertible Preferred Stock	5,000	50,000	D

F1The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-222374).
F2The warrants are exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and will expire on the later of (i) the one-year anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.